Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

被引：0
|
作者：
Baudin, E. [1 ]
Hoersch, D. [2 ]
Singh, S. [3 ]
Caplin, M. [4 ]
Ferone, D. [5 ]
Wolin, E. [6 ]
Capdevila, J. [7 ]
Buikhuisen, W. [8 ]
Raderer, M. [9 ]
Houchard, A. [10 ]
Thanh, Truong X. M. [10 ]
Reidy-Lagunes, D. [11 ]
机构：
[1] Gustave Roussy Inst Cancerol, Villejuif, France
[2] Zent Klin Bad Berka GmbH, Bad Berka, Germany
[3] Sunnybrook HSC, Sunnybrook Odette Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[4] Royal Free Hosp, Sch Med, Neuroendocrine Tumour Unit, London, England
[5] Univ Genoa, Neuroendocrine Tumour Unit, Dept Internal Med & Med Specialties, Genoa, Italy
[6] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[7] Vall dHebron Univ Hosp, Dept Med Oncol, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[8] Netherlands Canc Inst, Dept Thorax Oncol, Amsterdam, Netherlands
[9] Med Univ Vienna, Vienna, Austria
[10] Ipsen, Boulogne Billancourt, France
[11] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
bronchopulmonary neuroendocrine tumor; lanreotide autogel/depot; spinet; tumor growth rate; typical/atypical carcinoid;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I03
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [1] Lanreotide Autogel/Depot (LAN) in Patients With Advanced Bronchopulmonary (BP) Neuroendocrine Tumors (NETs): Results From the Phase 3 SPINET Study
    Reidy-Lagunes, Diane
    Horsch, Dieter
    Singh, Simron
    Caplin, Martyn E.
    Ferone, Diego
    Wolin, Edward M.
    Capdevila, Jaume
    Buikhuisen, Wieneke
    Raderer, Markus
    Dansin, Eric
    Grohe, Christian
    Houchard, Aude
    Truong-Thanh, Xuan-Mai
    Baudin, Eric
    PANCREAS, 2022, 51 (03) : E37 - E38
  • [2] Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study
    Baudin, E.
    Horsch, D.
    Singh, S.
    Caplin, M. E.
    Ferone, D.
    Wolin, E. M.
    Capdevila, J.
    Buikhuisen, W. A.
    Raderer, M.
    Dansin, E.
    Grohe, C.
    Houchard, A.
    Thanh, X-M. Truong
    Reidy-Lagunes, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S906 - S906
  • [3] Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study
    Caplin, Martyn E.
    Pavel, Marianne E.
    Ruszniewski, Philippe
    Liyanage, Nilani
    Massien, Christine
    Dromain, Clarisse
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study
    Baudin, E.
    Capdevila, J.
    Hoersch, D.
    Singh, S.
    Caplin, M. E.
    Wolin, E. M.
    Buikhuisen, W.
    Raderer, M.
    Dansin, E.
    Grohe, C.
    Ferone, D.
    Houchard, A.
    Truong-Thanh, X-M
    Reidy-Lagunes, D.
    ENDOCRINE-RELATED CANCER, 2024, 31 (09)
  • [5] Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study
    Baudin, E.
    Hoersch, D.
    Singh, S.
    Caplin, M.
    Ferone, D.
    Wolin, E.
    Capdevila, J.
    Buikhuisen, W.
    Raderer, M.
    Houchard, A.
    Thanh, Truong X. M.
    Reidy-Lagunes, D.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 166 - 166
  • [6] Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [8] Lanreotide Autogel/ Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study
    Reidy-Lagunes, D.
    Kulke, M. H.
    Wolin, E. M.
    Singh, S.
    Ferone, D.
    Hoersch, D.
    Mirakhur, B.
    Hoffmanns, P.
    Houchard, A.
    Caplin, M.
    Baudin, E.
    NEUROENDOCRINOLOGY, 2017, 105 : 209 - 209
  • [9] Antitumor Effects With Lanreotide Autogel/Depot (LAN) in Patients With Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study
    Caplin, Martyn E.
    Phan, Alexandria T.
    Ruszniewski, Philippe
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 351 - 352
  • [10] SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors
    Reidy-Lagunes, Diane
    Kulke, Matthew
    Wolin, Edward
    Singh, Simron
    Ferone, Diego
    Mirakhur, Beloo
    Hoffmanns, Philipp
    Houchard, Aude
    Caplin, Martyn
    Baudin, Eric
    PANCREAS, 2017, 46 (03) : 451 - 451
12345